Premature Labor (Tocolysis) - Global Pipeline Review, H1 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--May 28, 2019--
The “Premature Labor (Tocolysis) - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Premature Labor (Tocolysis) - Pipeline Review, H1 2019 provides comprehensive information on the therapeutics under development for Premature Labor (Tocolysis) (Women’s Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Premature Labor (Tocolysis) (Women’s Health) pipeline guide also reviews of key players involved in therapeutic development for Premature Labor (Tocolysis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Reasons to Buy
Recent News & Press Releases
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/aczng2
View source version on businesswire.com:https://www.businesswire.com/news/home/20190528005293/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Women’s Health
KEYWORD: EUROPE ASIA PACIFIC NORTH AMERICA
INDUSTRY KEYWORD: HEALTH OTHER HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 05/28/2019 05:49 AM/DISC: 05/28/2019 05:49 AM